Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice.
Lung cancer
Re-biopsy
Treatment
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
23
07
2018
accepted:
24
08
2018
pubmed:
31
8
2018
medline:
28
2
2019
entrez:
31
8
2018
Statut:
ppublish
Résumé
The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. This review reports that the significance of a re-biopsy varies depending on the clinical situation.
Identifiants
pubmed: 30159691
doi: 10.1007/s10147-018-1344-x
pii: 10.1007/s10147-018-1344-x
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
41-45Références
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
J Clin Oncol. 2004 Oct 1;22(19):3852-9
pubmed: 15326195
Ann Oncol. 2004 Dec;15(12):1782-9
pubmed: 15550583
Oncol Rep. 2007 Feb;17(2):313-7
pubmed: 17203166
Cancer. 2007 Mar 1;109(5):939-48
pubmed: 17285602
J Thorac Oncol. 2007 Jan;2(1):96
pubmed: 17410021
J Thorac Oncol. 2007 Jul;2(7):632-7
pubmed: 17607119
Jpn J Clin Oncol. 2013 Nov;43(11):1115-23
pubmed: 24082005
Cancer Chemother Pharmacol. 2014 May;73(5):943-50
pubmed: 24633759
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
J Thorac Oncol. 2014 Aug;9(8):e64-5
pubmed: 25157783
Chest. 2014 Dec;146(6):e222-e225
pubmed: 25451370
Jpn J Clin Oncol. 2015 Jun;45(6):603-4
pubmed: 25920396
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
Int J Clin Oncol. 2016 Feb;21(1):81-7
pubmed: 26093520
J Thorac Oncol. 2015 Nov;10(11):1553-9
pubmed: 26309190
Lancet. 2016 Apr 9;387(10027):1540-50
pubmed: 26712084
Sci Rep. 2016 Jan 29;6:20090
pubmed: 26822379
Clin Cancer Res. 2016 Sep 15;22(18):4585-93
pubmed: 27225694
Clin Lung Cancer. 2016 Nov;17(6):602-605
pubmed: 27405684
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
Lung Cancer. 2016 Sep;99:166-71
pubmed: 27565935
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Ann Oncol. 2017 Jul 1;28(7):1532-1539
pubmed: 28407039
Lancet. 2017 Jul 1;390(10089):29-39
pubmed: 28501140
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Lung Cancer. 2017 Sep;111:65-68
pubmed: 28838401
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Oncotarget. 2017 Nov 21;8(64):107630-107639
pubmed: 29296194
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Oncotarget. 2018 Jun 29;9(50):29525-29531
pubmed: 30034635